Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

soticlestat

- PMLiVE

Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1

The phase 3 results show improvements in daily function, cognition and nighttime sleep

- PMLiVE

UCB presentation highlights impacts of epilepsy on daily life

The data underlines the consequences of disrupted sleep for patients and caregivers

Genetic Digital at the EHP Awards

EpilepsyMeds receives Highly Commended recognition at Excellence in Healthcare Partnership Awards 2026

EpilepsyMeds received Highly Commended recognition at the Excellence in Healthcare Partnership Awards 2026, celebrating the collaboration between Desitin Pharma, ChangeMed and Genetic Digital in advancing epilepsy care.

Genetic Digital

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE

BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

Epilepsy meds app silver award at PMi Awards

Genetic Digital Wins Silver at PM Society Digital Awards for Epilepsy Meds Clinical Support App

Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.

Genetic Digital

Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds.

Genetic Digital Shortlisted for PM Society Digital Award for Epilepsy Meds App

Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The...

Genetic Digital

- PMLiVE

UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

- PMLiVE

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

- PMLiVE

Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

- PMLiVE

Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links